e-learning
resources
Barcelona 2013
Monday, 09.09.2013
Cystic fibrosis: basic and applied science
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The chemokine decoy PA401 decreases interleukin-8 and chemotactic activity of cystic fibrosis airway samples
O. J. McElvaney, D. A. Bergin, T. Adage, J. H. Slingsby, A. J. Kungl, M. R. Bartley, E. P. Reeves, N. G. McElvaney (Dublin, Ireland; Reininghausstrasse, Austria)
Source:
Annual Congress 2013 –Cystic fibrosis: basic and applied science
Session:
Cystic fibrosis: basic and applied science
Session type:
Poster Discussion
Number:
2108
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
O. J. McElvaney, D. A. Bergin, T. Adage, J. H. Slingsby, A. J. Kungl, M. R. Bartley, E. P. Reeves, N. G. McElvaney (Dublin, Ireland; Reininghausstrasse, Austria). The chemokine decoy PA401 decreases interleukin-8 and chemotactic activity of cystic fibrosis airway samples. Eur Respir J 2013; 42: Suppl. 57, 2108
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Emerging classes of drugs for the treatment of obstructive lung disease
Eosinophils and airway nerves in asthma
Related content which might interest you:
α1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients
Source: Eur Respir J 2007; 29: 240-250
Year: 2007
Regulation of interleukin-8 by miR-17 during chronic inflammation in cystic fibrosis
Source: International Congress 2015 – The multiple faces of host defense
Year: 2015
Anti-inflammatory cytokines in cystic fibrosis lung disease
Source: Eur Respir J 2006; 28: 581-587
Year: 2006
Characterization of cystic fibrosis airway epithelium
in vitro
Source: Annual Congress 2005 - Cystic fibrosis lung disease: pieces of the puzzle
Year: 2005
Alveolar macrophages and CC chemokines are increased in children with cystic fibrosis
Source: Eur Respir J 2009; 34: 655
Year: 2009
Disturbance of pro-inflammatory cytokine production in patients with cystic fibrosis lung disease
Source: Eur Respir J 2005; 26: Suppl. 49, 404s
Year: 2005
CFTR-dependent deficiency in alternatively-activated macrophages in cystic fibrosis
Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring
Year: 2016
Pro-inflammatory cytokines in cystic fibrosis lungs
Source: Eur Respir J 2005; 26: Suppl. 49, 403s
Year: 2005
Chemokine receptors in a regulation of interstitial lung fibrosis and inflammation
Source: Annual Congress 2008 - Miscellaneous aspects of interstitial lung disease
Year: 2008
Raised interleukin-17 is immunolocalised to neutrophils in cystic fibrosis lung disease
Source: Eur Respir J 2011; 37: 1378-1385
Year: 2011
Expression of HCLCA1 in cystic fibrosis lungs is associated with mucus overproduction
Source: Eur Respir J 2004; 23: 846-850
Year: 2004
Fluticasone reduces IL-6 and IL-8 production of cystic fibrosis bronchial epithelial cells via IKK-β kinase pathway
Source: Eur Respir J 2003; 21: 574-581
Year: 2003
The role of chemokines and cytokines in lung fibrosis
Source: Eur Respir Rev 2008; 17: 151-156
Year: 2008
PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced pulmonary fibrosis by regulating inflammatory cytokines in bronchoalveolar fluid
Source: Annual Congress 2013 –Novel mechanisms in lung injury
Year: 2013
The cytokine interleukin-17 is raised in the airway of people with cystic fibrosis
Source: Annual Congress 2009 - Cystic fibrosis: understanding a complex disease
Year: 2009
Thalidomide reduces IL-18, IL-8 and TNF-α release from alveolar macrophages in interstitial lung disease
Source: Eur Respir J 2006 Oct 01;28(4):824-831
Year: 2006
Role of TGF-beta and IFN-gamma in interstitial pulmonary fibrosis
Source: Eur Respir J 2004; 24: Suppl. 48, 719s
Year: 2004
Differential expression of IL-33 and HMGB1 in the lungs of stable cystic fibrosis patients
Source: Eur Respir J 2014; 44: 802-805
Year: 2014
Expression of macrophage migration inhibitory factor in patients with idiopathic pulmonary fibrosis
Source: International Congress 2015 – Interstitial lung diseases II
Year: 2015
Circulating inflammatory cytokines in adult cystic fibrosis patients
Source: Annual Congress 2009 - Cystic fibrosis: advances in clinical research
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept